TigerResearch/tigerbot-earning-plugin huggingface dataset:
账龄|期末账面余额
1年以内|
其中:1 年以内分项|
一年以内|1,066,113,840.78
1年以内小计|1,066,113,840.78
1至2 年|4,357,921.08
2至3 年|785,032.07
3年以上|
3至4 年|3,822,448.74
4至5 年|2,176,918.34
5年以上|
合计|1,077,256,161.01
|金额|比例(%)|金额|计提比例(%)|价值|金额|比例(%)|金额|计提比例(%)|价值
按单项计提坏账准备|5,979,417.08|0.56|5,979,417.08|100.00||5,979,417.08|0.76|5,979,417.08|100|
其中:||||||||||
中经汇通电子商务有限公司|2,176,918.34|0.20|2,176,918.34|100.00||2,176,918.34|0.28|2,176,918.34|100.00|
江西华尔康药业有限公司|3,802,498.74|0.36|3,802,498.74|100.00||3,802,498.74|0.48|3,802,498.74|100.00|
按组合计提坏账准备|1,071,276,743.93|99.44|53,908,465.53|5.03|1,017,368,278.40|778,462,216.75|99.24|39,238,597.16|5.04|739,223,619.59
其中:||||||||||
按账龄计提坏账准备|1,071,276,743.93|99.44|53,908,465.53|5.03|1,017,368,278.40|778,462,216.75|99.24|39,238,597.16|5.04|739,223,619.59
合计|1,077,256,161.01|/|59,887,882.61|/|1,017,368,278.40|784,441,633.83|/|45,218,014.24|/|739,223,619.59
名称|期末余额|||
|账面余额|坏账准备|计提比例(%)|计提理由
中经汇通电子商务有限公司|2,176,918.34|2,176,918.34|100|已起诉并胜诉,但预计收回存在困难
江西华尔康药业有限公司|3,802,498.74|3,802,498.74|100|预计款项收回存在困难
合计|5,979,417.08|5,979,417.08|100|/
名称|期末余额||
|应收账款|坏账准备|计提比例(%)
1年以内|1,066,113,840.78|53,305,692.01|5
1-2 年|4,357,921.08|435,792.11|10
2-3 年|785,032.07|157,006.41|20
3-4 年|19,950.00|9,975.00|50
合计|1,071,276,743.93|53,908,465.53|5.03
类别|期初余额|本期变动金额||||期末余额
||计提|收回或转回|转销或核销|其他变动|
单项计提坏账准备|5,979,417.08|||||5,979,417.08
按组合计提坏账准备|39,238,597.16|23,600,254.29||10,465,645.60|1,535,259.68|53,908,465.53
合计|45,218,014.24|23,600,254.29||10,465,645.60|1,535,259.68|59,887,882.61
项目|核销金额
实际核销的应收账款|10,465,645.60
单位名称|期末余额|占应收账款期末余额合计数的比例(%)|坏账准备期末余额
客户A|28,349,788.18|2.63|1,417,489.41
客户B|24,953,252.20|2.32|1,247,662.61
客户C|24,059,935.87|2.23|1,202,996.79
客户D|21,821,429.24|2.03|1,091,071.46
客户E|21,564,411.34|2|1,078,220.57
合计|120,748,816.83|11.21|6,037,440.84
项目|期末余额|期初余额
银行承兑汇票|4,441,288.79|4,600,658.80
合计|4,441,288.79|4,600,658.80
(1)期末公司无质押的应收票据情况。
项目|期末终止确认金额
银行承兑汇票|2,899,829.30
小计|2,899,829.30
账龄|期末余额||期初余额|
|金额|比例(%)|金额|比例(%)
1年以内|600,167,339.98|96.69|133,370,884.25|91.55
1至2 年|12,243,825.46|1.97|7,280,333.15|5
2至3 年|4,255,437.89|0.69|4,660,199.80|3.2
3年以上|4,039,984.82|0.65|370,070.70|0.25
合计|620,706,588.15|100|145,681,487.90|100
单位名称|期末余额|占预付款项期末余额合计数的比例(%)
供应商A|124,681,299.74|20.09
供应商B|46,246,462.33|7.45
供应商C|28,900,000.00|4.66
供应商D|23,743,682.07|3.82
供应商E|18,903,310.59|3.04
合计|242,474,754.73|39.06
项目|期末余额|期初余额
应收利息||
应收股利||
其他应收款|368,236,479.29|308,184,287.57
合计|368,236,479.29|308,184,287.57
账龄|期末账面余额
1年以内|
其中:1 年以内分项|
一年以内|179,816,289.97
1年以内小计|179,816,289.97
1至2 年|154,701,482.21
2至3 年|13,212,757.49
3年以上|
3至4 年|6,233,303.65
4至5 年|11,266,603.60
5年以上|23,646,025.75
合计|388,876,462.67
款项性质|期末账面余额|期初账面余额
门店备用金|17,598,729.42|12,913,475.40
除门店备用金之外的其他各类备用金及押金|212,181,452.07|200,822,194.66
员工借支往来款|33,541,836.41|28,401,484.42
保证金|70,000,000.00|30,000,000.00
其他|55,554,444.77|52,882,100.93
合计|388,876,462.67|325,019,255.41
坏账准备|第一阶段|第二阶段|第三阶段|合计
|未来12个月预期信用损失|整个存续期预期信用损失(未发生信用减值)|整个存续期预期信用损失(已发生信用减值)|
2022年1月1日余额|15,734,988.02|978,223.96|121,755.86|16,834,967.84
2022年1月1日余额在本期||||
--转入第二阶段|-1,073,810.34|1,073,810.34||
--转入第三阶段||-17,128.47|17,128.47|
--转回第二阶段||||
--转回第一阶段||||
本期计提|8,589,148.22|1,209,661.78|2,769.37|9,801,579.37
本期转回||||
本期转销|5,113,221.55|1,096,946.90||6,210,168.45
其他变动|213,604.62|||213,604.62
2022年12月31日余额|18,350,708.97|2,147,620.71|141,653.70|20,639,983.38
项目|核销金额
实际核销的其他应收款|6,210,168.45
单位名称|款项的性质|期末余额|账龄|占其他应收款期末余额合计数的比例(%)|坏账准备期末余额
往来单位A|押金|70,100,000.00|1 年以内|18.03|3,505,000.00
往来单位B|往来款|4,882,778.97|1-2 年|1.26|488,277.90
往来单位C|往来款|2,584,867.93|1 年以内|0.66|258,486.79
往来单位D|促销服务费|2,319,500.00|1-2 年|0.60|115,975.00
往来单位E|押金|1,336,400.00|5 年以上|0.34|66,820.00
合计|/|81,223,546.90|/|20.89|4,434,559.69
项目|期末余额|||期初余额||
|账面余额|存货跌价准备/合同履约成本减值准备|账面价值|账面余额|存货跌价准备/合同履约成本减值准备|账面价值
原材料|161,931,549.28||161,931,549.28|160,379,952.12||160,379,952.12
在产品||||||
库存商品|3,541,562,805.41|9,046,402.92|3,532,516,402.49|3,434,056,548.18|16,416,234.50|3,417,640,313.68
周转材料||||||
消耗性生物资产||||||
合同履约成本||||||
发出商品|138,637,298.77||138,637,298.77|14,514,552.46||14,514,552.46
低值易耗品|1,369,634.53||1,369,634.53|3,499,862.54||3,499,862.54
生产成本|38,005,897.88||38,005,897.88|34,111,275.44||34,111,275.44
合计|3,881,507,185.87|9,046,402.92|3,872,460,782.95|3,646,562,190.74|16,416,234.50|3,630,145,956.24
项目|期初余额|本期增加金额||本期减少金额||期末余额
||计提|其他|转回或转销|其他|
原材料||||||
在产品||||||
库存商品|16,416,234.50|8,918,331.60|4,596.59|16,292,759.77||9,046,402.92
周转材料||||||
消耗性生物资产||||||
合同履约成本||||||
合计|16,416,234.50|8,918,331.60|4,596.59|16,292,759.77||9,046,402.92
项目|确定可变现净值的具体依据|本期转销存货跌价准备的原因
库存商品|相关产成品估计售价减去估计的销售费用以及相关税费后的金额确定可变现净值|本期已将期初计提存货跌价准备的存货售出
如按预期信用损失一般模型计提坏账准备,请参照其他应收款披露:□适用□不适用
项目|期末余额|期初余额
合同取得成本||
应收退货成本||
待摊租金|38,381,656.53|41,385,293.95
增值税待抵扣及待认证进项税|123,666,312.22|57,495,040.83
其他待摊费用|38,686,911.57|37,011,392.92
预缴税费|644,006.86|2,408,330.85
合计|201,378,887.18|138,300,058.55
被投资单位|期初余额|本期增减变动||||||||期末余额|减值准备期末余额
||追加投资|减少投资|权益法下确认的投资损益|其他综合收益调整|其他权益变动|宣告发放现金股利或利润|计提减值准备|其他||
一、合营企业|||||||||||
小计|||||||||||
二、联营企业|||||||||||
浙江好簿网络有限公司|||||||||||5,008,950.91
正向(广州)教育科技发展有限公司|188,335.29|||-45,837.65||||||142,497.64|
小计|188,335.29|||-45,837.65||||||142,497.64|5,008,950.91
合计|188,335.29|||-45,837.65||||||142,497.64|5,008,950.91
项目|期末余额|期初余额
权益工具投资|132,017,000.00|149,981,000.00
合计|132,017,000.00|149,981,000.00
项目|期末余额|期初余额
固定资产|1,407,868,582.82|1,154,430,328.67
固定资产清理||
合计|1,407,868,582.82|1,154,430,328.67
项目|房屋及建筑物|机器设备|电子设备|运输工具|其他设备|合计
一、账面原值:||||||
1.期初余额|800,433,932.19|165,693,679.59|400,872,436.76|72,445,753.16|479,832,848.26|1,919,278,649.96
2.本期增加金额|275,852,326.79|40,629,979.70|72,201,855.77|15,729,813.51|61,109,485.97|465,523,461.74
(1)购置|17,694,633.31|27,251,832.10|68,294,619.76|13,974,260.71|57,603,642.52|184,818,988.40
(2)在建工程转入|258,157,693.48|13,049,517.47|40,129.31||96,260.18|271,343,600.44
(3)企业合并增加||328,630.13|3,867,106.70|1,755,552.80|3,409,583.27|9,360,872.90
3.本期减少金额||2,865,412.08|20,997,233.90|9,314,554.96|18,826,446.50|52,003,647.44
(1)处置或报废||2,865,412.08|20,997,233.90|9,314,554.96|18,826,446.50|52,003,647.44
4.期末余额|1,076,286,258.98|203,458,247.21|452,077,058.63|78,861,011.71|522,115,887.73|2,332,798,464.26
二、累计折旧||||||
1.期初余额|163,407,629.01|78,855,486.54|217,180,640.54|36,997,614.45|268,406,950.75|764,848,321.29
2.本期增加金额|35,153,412.83|27,344,206.98|61,286,667.54|6,616,921.86|66,806,966.38|197,208,175.59
(1)计提|35,153,412.83|27,280,538.90|59,351,992.01|6,205,433.13|64,877,274.51|192,868,651.38
(2)企业合并增加||63,668.08|1,934,675.53|411,488.73|1,929,691.87|4,339,524.21
3.本期减少金额||1,635,926.88|15,808,234.82|6,552,627.65|13,129,826.09|37,126,615.44
(1)处置或报废||1,635,926.88|15,808,234.82|6,552,627.65|13,129,826.09|37,126,615.44
4.期末余额|198,561,041.84|104,563,766.64|262,659,073.26|37,061,908.66|322,084,091.04|924,929,881.44
三、减值准备||||||
1.期初余额||||||
2.本期增加金额||||||
(1)计提||||||
3.本期减少金额||||||
(1)处置或报废||||||
4.期末余额||||||
四、账面价值||||||
1.期末账面价值|877,725,217.14|98,894,480.57|189,417,985.37|41,799,103.05|200,031,796.69|1,407,868,582.82
2.期初账面价值|637,026,303.18|86,838,193.05|183,691,796.22|35,448,138.71|211,425,897.51|1,154,430,328.67
项目|账面原值|累计折旧|账面价值|备注
房屋及建筑物|51,545,110.74|102,016.37|51,443,094.37|新建资产短期内暂未投入使用
合计|51,545,110.74|102,016.37|51,443,094.37|
项目|账面价值|未办妥产权证书的原因
漯河大参林医药产业园二期楼库|27,670,995.31|正在办理
汕头大参林医药产业基地项目物流仓库|70,916,272.93|正在办理
汕头大参林医药产业基地项目通用厂房|51,443,094.37|正在办理
广西南宁大参林中心项目4 号楼|104,829,587.82|2023 年3 月已办妥
河源大参林坚基春天里商铺|9,130,776.00|正在办理
小计|263,990,726.43|
项目|期末余额|期初余额
在建工程|1,049,086,353.61|765,668,826.11
工程物资||
合计|1,049,086,353.61|765,668,826.11
项目|期末余额|||期初余额||
|账面余额|减值准备|账面价值|账面余额|减值准备|账面价值
营运中心建设项目|394,759,029.48||394,759,029.48|296,444,437.61||296,444,437.61
汕头大参林医药产业基地项目(粤东运营中心)|87,007,091.84||87,007,091.84|165,693,893.03||165,693,893.03
茂名大参林生产基地立库项目|34,489,382.32||34,489,382.32|25,503,253.21||25,503,253.21
枣庄阿胶厂房(一期)|7,059,611.10||7,059,611.10|1,864,088.90||1,864,088.90
南宁大参林中心项目|209,312,030.21||209,312,030.21|222,802,619.08||222,802,619.08
南昌大参林产业基地项目(一期)|51,270,236.32||51,270,236.32|19,678,912.80||19,678,912.80
大参林一号产业基地项目|180,638,945.34||180,638,945.34|10,257,446.49||10,257,446.49
漯河大参林医药产业园二期楼库||||23,424,174.99||23,424,174.99
漯河大参林医药产业园二期立库|24,471,787.94||24,471,787.94|||
医疗器械、医护用品、中药饮片生产项目|53,872,694.57||53,872,694.57|||
其他项目|6,205,544.49||6,205,544.49|||
合计|1,049,086,353.61||1,049,086,353.61|765,668,826.11||765,668,826.11
项目名称|预算数|期初余额|本期增加金额|本期转入固定资产金额|本期其他减少金额|期末余额|工程累计投入占预算比例(%)|工程进度|利息资本化累计金额|其中:本期利息资本化金额|本期利息资本化率(%)|资金来源
营运中心建设项目[ 注1]|750,000,000|296,444,437.61|98,314,591.87|||394,759,029.48|86.21|90%|4,256,930.49|||可转债及借款
汕头大参林医药产业基地项目( 粤东运营中心)|208,500,000|165,693,893.03|57,272,634.22|135,959,435.41||87,007,091.84|106.94|96%|8,092,981.65|4,058,288.87|3.9|可转债及自有资金
茂名大参林生产基地立库项目|45,000,000|25,503,253.21|8,986,129.11|||34,489,382.32|76.64|80%|1,583,425.61|1,583,425.61|3.9|可转债及自有资金
枣庄阿胶厂房( 一期)[注2]|120,000,000|1,864,088.90|6,146,382.27|950,860.07||7,059,611.10|35.02|35%|1,917,208.35|||自有资金
南宁大参林中心项目|270,000,000|222,802,619.08|91,965,142.35|105,455,731.22||209,312,030.21|116.58|95%|13,668,911.01|8,016,678.64|3.9|可转债及自有资金
南昌大参林产业基地项目( 一期)|148,780,000|19,678,912.80|31,591,323.52|||51,270,236.32|34.46|85%|8,063,939.43|5,054,998.29|3.9|可转债及自有资金
大参林一号产业基地项目|550,000,000|10,257,446.49|170,381,498.85|||180,638,945.34|32.84|35%||||自有资金
漯河大参林医药产业园二期楼库|30,000,000|23,424,174.99|5,530,298.75|28,954,473.74|||96.51|100%||||自有资金
漯河大参林医药产业园二期立库|22,000,000||24,471,787.94|||24,471,787.94|111.24|85%||||自有资金
医疗器械、医护用品、中药饮片生产项目|400,000,000||53,872,694.57|||53,872,694.57|13.47|15%||||自有资金
其他项目|||6,228,644.49|23,100.00||6,205,544.49||||||自有资金
合计|2,544,280,000|765,668,826.11|554,761,127.94|271,343,600.44||1,049,086,353.61|/|/|37,583,396.54|18,713,391.41|/|/
[注1] 营运中心建设项目预算金额包括购买土地价款
[注2] 枣庄阿胶厂房(一期)预算金额包括购买土地和生产批文价款
项目|房屋及建筑物|合计
一、账面原值||
1.期初余额|6,168,170,293.44|6,168,170,293.44
2.本期增加金额|1,280,239,472.53|1,280,239,472.53
(1) 租入|1,141,195,127.17|1,141,195,127.17
(2) 合并增加|139,044,345.36|139,044,345.36
3.本期减少金额|1,025,971,482.19|1,025,971,482.19
(1) 处置|1,025,971,482.19|1,025,971,482.19
4.期末余额|6,422,438,283.78|6,422,438,283.78
二、累计折旧||
1.期初余额|2,434,562,357.92|2,434,562,357.92
2.本期增加金额|1,108,487,902.72|1,108,487,902.72
(1)计提|1,070,058,226.57|1,070,058,226.57
(2) 合并增加|38,429,676.15|38,429,676.15
3.本期减少金额|758,631,862.83|758,631,862.83
(1)处置|758,631,862.83|758,631,862.83
4.期末余额|2,784,418,397.81|2,784,418,397.81
三、减值准备||
1.期初余额||
2.本期增加金额||
(1)计提||
3.本期减少金额||
(1)处置||
4.期末余额||
四、账面价值||
1.期末账面价值|3,638,019,885.97|3,638,019,885.97
2.期初账面价值|3,733,607,935.52|3,733,607,935.52
项目|土地使用权|专利权|软件|商标|非专利技术|合计
一、账面原值||||||
1.期初余额|494,480,912.90||137,536,346.83|9,756,663.22|73,126,953.69|714,900,876.64
2.本期增加金额|13,856,714.30||38,203,743.82|155,903.49|1,020,018.35|53,236,379.96
(1)购置|13,856,714.30||15,341,248.58|155,903.49|71,287.13|29,425,153.50
(2)内部研发|||22,509,173.29||948,731.22|23,457,904.51
(3)企业合并增加|||353,321.95|||353,321.95
3.本期减少金额|||1,367,891.98|||1,367,891.98
(1)处置|||1,367,891.98|||1,367,891.98
4.期末余额|508,337,627.20||174,372,198.67|9,912,566.71|74,146,972.04|766,769,364.62
二、累计摊销||||||
1.期初余额|33,237,631.77||46,182,375.17|1,495,388.82|15,186,466.82|96,101,862.58
2.本期增加金额|11,592,194.29||16,181,345.19|592,332.49|6,269,042.33|34,634,914.30
(1)计提|11,592,194.29||15,993,848.73|592,332.49|6,269,042.33|34,447,417.84
(2)合并增加|||187,496.46|||187,496.46
3.本期减少金额|||1,158,091.39|||1,158,091.39
(1)处置|||1,158,091.3|||1,158,091.39
|||9|||
4.期末余额|44,829,826.06||61,205,628.97|2,087,721.31|21,455,509.15|129,578,685.49
三、减值准备||||||
1.期初余额||||||
2.本期增加金额||||||
(1)计提||||||
3.本期减少金额||||||
(1)处置||||||
4.期末余额||||||
四、账面价值||||||
1.期末账面价值|463,507,801.14||113,166,569.70|7,824,845.40|52,691,462.89|637,190,679.13
2.期初账面价值|461,243,281.13||91,353,971.66|8,261,274.40|57,940,486.87|618,799,014.06
本期末通过公司内部研发形成的无形资产占无形资产余额的比例12.71%
项目|期初余额|本期增加金额|||本期减少金额|||期末余额
||内部开发支出|其他||确认为无形资产|转入当期损益||
药品批文工艺验证|53,009,412.99|16,675,655.85|1,684,189.43||948,731.22|7,057,331.68||63,363,195.37
软件开发|4,601,851.74|33,190,142.82|11,360,818.21||22,509,173.29|26,643,639.48||
合计|57,611,264.73|49,865,798.67|13,045,007.64||23,457,904.51|33,700,971.16||63,363,195.37
被投资单位名称或形成商誉的事项|期初余额|本期增加||本期减少||期末余额
||企业合并形成的|本期其他增加|处置|其他|
北京金康源生物医药技术有限公司|2,584,373.58|||||2,584,373.58
江西大参林众康连锁药店有限公司|42,384,491.42|||||42,384,491.42
许昌大参林保元堂药店连锁有限公司|28,404,369.48|||||28,404,369.48
广东大参林柏康连锁药店有限公司|11,575,921.38|||||11,575,921.38
赣州大参林连锁药店有限公司|50,226,175.96|||||50,226,175.96
济源大参林心连心连锁药店有限公司|8,830,836.03|||||8,830,836.03
漳州市大国晟医药销售有限公司|65,838,170.96|||||65,838,170.96
安阳千年健19家门店资产及业务|17,300,000.00|||||17,300,000.00
巩义康美10家门店资产及业务|11,700,000.00|||||11,700,000.00
新密麦迪森19家门店资产及业务|11,850,000.00|||||11,850,000.00
方城健康人33家门店资产及业务|36,000,000.00|||||36,000,000.00
郁南正方大药房12家门店资产及业务|20,500,000.00|||||20,500,000.00
信宜市泓璐38家门店资产及业务|67,880,000.00|||||67,880,000.00
化州一爱堂17家门店资产及业务|33,340,000.00|||||33,340,000.00
湛江鸿中15家门店资产及业务|19,488,000.00|||||19,488,000.00
信阳豫辉45家门店资产及业务|19,300,000.00|||||19,300,000.00
江西会好康7家门店资产及业务|86,845,223.00|||||86,845,223.00
保定市盛世华兴医药连锁有限公司|94,357,413.29|||||94,357,413.29
广州柏和药店连锁有限公司|34,042,742.34|||||34,042,742.34
西安欣康大药房连锁有限公司|43,520,499.31|||||43,520,499.31
鸡西市大参林灵峰药房连锁有限公司|38,401,659.42|||||38,401,659.42
广东康益百医药有限公司|4,800,000.00|||||4,800,000.00
南通市江海大药房|108,364,954.84|||||108,364,954.84
连锁有限公司||||||
阳春市八方大药房门店资产及业务|64,160,000.00|||||64,160,000.00
阳江市仁信医药门店资产及业务|25,800,000.00|||||25,800,000.00
濮阳济世健民大药房门店及资产|17,464,900.00|||||17,464,900.00
温迪36家门店资产及业务|11,557,572.59|||||11,557,572.59
河南佐今明大药房健康管理股份有限公司|104,792,346.92|||||104,792,346.92
湛江天马大药房连锁有限公司|161,940,839.74|||||161,940,839.74
保定市益民医药零售连锁有限公司|32,561,825.16|||||32,561,825.16
信阳大参林百姓福医药连锁有限公司|24,309,595.10|||||24,309,595.10
驻马店大参林百姓连锁药店有限公司|24,890,688.19|||||24,890,688.19
保定市旭康医药有限公司|6,459,455.84|||||6,459,455.84
常州市健安堂大药房有限公司|17,610,818.83|||||17,610,818.83
成都一丰立康医药连锁有限责任公司|40,436,522.71|||||40,436,522.71
大参林泰华(绥化)医药连锁有限公司|105,570,510.57|||||105,570,510.57
大参林福斯特(大庆)医药连锁有限公司|24,139,892.89|||||24,139,892.89
德阳大成家人健康连锁药房有限公司|28,790,154.21|||||28,790,154.21
广州仁和药房网医药科技有限公司|3,708,943.13|||||3,708,943.13
广州市利斯达康健康大药房有限责任公司|1,059,622.04|||||1,059,622.04
河北益友医药连锁有限公司|21,668,617.75|||||21,668,617.75
河南大参林炎黄大药房连锁有限公司|54,032,068.23||816,911.44|||54,848,979.67
大参林灵峰(哈尔滨)医药连锁有限公司|43,362,369.44|||||43,362,369.44
大参林(湖北)药业连锁有限公司|24,586,849.07|||||24,586,849.07
淮滨县大参林康民堂医药连锁有限公|9,348,790.62|||||9,348,790.62
司||||||
鸡西市长寿堂创新药房连锁有限公司|34,382,106.93|||||34,382,106.93
牡丹江大参林天利医药连锁有限公司(曾用名:牡丹江天利医药连锁有限公司)|45,916,877.70||2,168,500.00|||48,085,377.70
南通遂生堂大药房有限公司|11,401,224.72|||||11,401,224.72
七台河天利医药连锁有限公司|8,972,065.85|||||8,972,065.85
齐齐哈尔大参林新特药品连锁有限公司|21,345,757.91|||||21,345,757.91
泰州市国泰大药房连锁有限公司|38,884,880.13||||2,383,500.00|36,501,380.13
大参林(扬州)医药连锁有限公司(曾用名:扬州市百姓人家医药连锁有限公司)|5,355,252.88|||||5,355,252.88
微山县润康广场医药连锁有限公司|33,071,545.82|||||33,071,545.82
重庆市万家燕大药房连锁有限公司|80,879,810.25||7,910,000.00|||88,789,810.25
盐城市建湖县时代大药房有限公司7家门店资产、商品及业务|15,000,000.00|||||15,000,000.00
梅州市益民大药房连锁有限公司20家门店资产、商品及业务|15,000,000.00|||||15,000,000.00
广东万寿堂医药连锁有限公司35家门店资产、商品及业务|32,530,000.00|||||32,530,000.00
宁都县仁济大药房11家门店资产、商品及业务|10,100,000.00|||||10,100,000.00
洛阳大参林连锁药店有限公司||27,327,567.29||||27,327,567.29
广东药交商务服务有限责任公司||11,195,845.60||||11,195,845.60
陕西万百泉大药房医药连锁有限公司||41,843,695.91||||41,843,695.91
大参林(湖北)药业有限公司(曾用名湖北百世康药业||4,294,756.51||||4,294,756.51
有限公司)||||||
大参林(河北)医药销售有限公司(曾用名河北翼保医药科技有限公司)||10,000,000.00||||10,000,000.00
辽宁博大维康药房连锁有限公司||92,225,316.81||||92,225,316.81
善康禾诺保险经纪有限公司||34,382,268.13||||34,382,268.13
杭州大参林大药房连锁有限公司(曾用名杭州怡生堂大药房连锁有限公司)||70,265,030.93||||70,265,030.93
杭州安和医药有限公司||2,918,663.72||||2,918,663.72
零星收购|1,200,914.39|1,247,342.02||283,750.60||2,164,505.81
合计|2,059,827,650.62|295,700,486.92|10,895,411.44|283,750.60|2,383,500.00|2,363,756,298.38
项目|江西大参林众康连锁药店有限公司|许昌大参林保元堂药店连锁有限公司|广东大参林柏康连锁药店有限公司|赣州大参林连锁药店有限公司[注1]
商誉账面余额1|42,384,491.42|28,404,369.48|11,575,921.38|60,326,175.96
商誉减值准备余额2||||
商誉账面价值3=1-2|42,384,491.42|28,404,369.48|11,575,921.38|60,326,175.96
未确认归属于少数股东权益的商誉价值4|18,164,782.04|27,290,472.64||42,785,261.00
调整后的商誉账面价值5=3+4|60,549,273.46|55,694,842.12|11,575,921.38|103,111,436.96
资产组的账面价值6|1,571,784.61|9,311,143.41|40,712,235.53|4,218,711.99
包含整体商誉的资产组账面价值7=5+6|62,121,058.07|65,005,985.53|52,288,156.91|107,330,148.95
包含商誉的资产组的可收回金额8|68,810,000.00|91,720,000.00|881,010,000.00|121,100,000.00
减值损失9=if( 8-7>0,0, 8-7)||||
其中:应确认的商誉减值损失10=if(9>5,5,9)||||
被审计单位享有的股权份额(11)|70.00%|51.00%|100.00%|54.00%
被审计单位应确认的商誉减值损失(12)=(11)*10||||
项目|济源大参林心连心连锁药店有限公司|漳州市大国晟医药销售有限公司|安阳千年健19 家门店资产及业务|巩义康美10 家门店资产及业务
商誉账面余额1|8,830,836.03|65,838,170.96|17,300,000.00|11,700,000.00
商誉减值准备余额2||||
商誉账面价值3=1-2|8,830,836.03|65,838,170.96|17,300,000.00|11,700,000.00
未确认归属于少数股东权益的商誉价值4|8,484,528.73|||
调整后的商誉账面价值5=3+4|17,315,364.76|65,838,170.96|17,300,000.00|11,700,000.00
资产组的账面价值6|5,533,101.42|5,023,892.04|718,421.56|889,452.58
包含整体商誉的资产组账面价值7=5+6|22,848,466.18|70,862,063.00|18,018,421.56|12,589,452.58
包含商誉的资产组的可收回金额8|62,430,000.00|85,250,000.00|25,930,000.00|26,430,000.00
减值损失9=if( 8-7>0,0, 8-7)||||
其中:应确认的商誉减值损失10=if(9>5,5,9)||||
被审计单位享有的股权份额(11)|51.00%|100.00%|100.00%|100.00%
被审计单位应确认的商誉减值损失(12)=(11)*10||||
项目|新密麦迪森19 家门店资产及业务|方城健康人33家门店资产及业务|郁南正方大药房12家门店业务及资产|信宜市泓璐38家门店业务及资产
商誉账面余额1|11,850,000.00|36,000,000.00|20,500,000.00|67,880,000.00
商誉减值准备余额2||||
商誉账面价值3=1-2|11,850,000.00|36,000,000.00|20,500,000.00|67,880,000.00
未确认归属于少数股东权益的商誉价值4||||
调整后的商誉账面价值5=3+4|11,850,000.00|36,000,000.00|20,500,000.00|67,880,000.00
资产组的账面价值6|956,510.27|2,916,958.28|664,614.67|3,497,661.18
包含整体商誉的资产组账面价值7=5+6|12,806,510.27|38,916,958.28|21,164,614.67|71,377,661.18
包含商誉的资产组的可收回金额8|13,860,000.00|48,260,000.00|43,360,000.00|164,800,000.00
减值损失9=if( 8-7>0,0, 8-7)||||
其中:应确认的商誉减值损失10=if(9>5,5,9)||||
被审计单位享有的股权份额(11)|100.00%|100.00%|100.00%|100.00%
被审计单位应确认的商誉减值损失(12)=(11)*10||||
项目|化州一爱堂17 家门店业务及资产|湛江鸿中15 家门店业务及资产|信阳豫辉45 家门店资产及业务|江西会好康7 家门店业务及资产
商誉账面余额1|33,340,000.00|19,488,000.00|19,300,000.00|86,845,223.00
商誉减值准备余额2||||
商誉账面价值3=2-1|33,340,000.00|19,488,000.00|19,300,000.00|86,845,223.00
未确认归属于少数股东权益的商誉价值4||||
调整后的商誉账面价值5=3+4|33,340,000.00|19,488,000.00|19,300,000.00|86,845,223.00
资产组的账面价值6|1,586,996.38|653,279.73|4,990,641.70|1,053,519.82
包含整体商誉的资产组账面价值7=5+6|34,926,996.38|20,141,279.73|24,290,641.70|87,898,742.82
包含商誉的资产组的可收回金额8|38,430,000.00|30,330,000.00|34,020,000.00|89,700,000.00
减值损失9=if( 8-7>0,0, 8-7)||||
其中:应确认的商誉减值损失10=if(9>5,5,9)||||
被审计单位享有的股权份额(11)|100.00%|100.00%|100.00%|100.00%
被审计单位应确认的商誉减值损失(12)=(11)*10||||
项目|保定市盛世华兴医药连锁有限公司|广州柏和药店连锁有限公司|西安欣康大药房连锁有限公司|鸡西市大参林灵峰药房连锁有限公司[注2]
商誉账面余额1|94,357,413.29|34,042,742.34|43,520,499.31|81,755,832.20
商誉减值准备余额2||||
商誉账面价值3=2-1|94,357,413.29|34,042,742.34|43,520,499.31|81,755,832.20
未确认归属于少数股东权益的商誉价值4|50,807,837.93|32,707,732.84|41,813,813.06|36,895,711.89
调整后的商誉账面价值5=3+4|145,165,251.22|66,750,475.18|85,334,312.37|118,651,544.09
资产组的账面价值6|7,040,496.15|9,808,203.41|8,766,210.03|6,457,359.85
包含整体商誉的资产组账面价值7=5+6|152,205,747.37|76,558,678.59|94,100,522.40|125,108,903.94
包含商誉的资产组的可收回金额8|180,700,000.00|221,410,000.00|238,820,000.00|145,670,000.00
减值损失9=if( 8-7>0,0, 8-7)||||
其中:应确认的商誉减值损失10=if(9>5,5,9)||||
被审计单位享有的股权份额(11)|65.00%|51.00%|51.00%|51.00%
被审计单位应确认的商誉减值损失(12)=(11)*10||||
项目|南通市江海大药房连锁有限公司[注3]|阳江市仁信医药门店资产及业务、阳春市八方大药房门店资产及业务|濮阳济世健民大药房门店及资产|温迪36 家门店资产及业务
商誉账面余额1|123,364,954.84|89,960,000.00|17,464,900.00|11,557,572.59
商誉减值准备余额2||||
商誉账面价值3=2-1|123,364,954.84|89,960,000.00|17,464,900.00|11,557,572.59
未确认归属于少数股东权益的商誉价值4|104,115,348.77|||
调整后的商誉账面价值5=3+4|227,480,303.61|89,960,000.00|17,464,900.00|11,557,572.59
资产组的账面价值6|26,855,211.10|2,784,178.65|803,380.97|2,671,095.99
包含整体商誉的资产组账面价值7=5+6|254,335,514.71|92,744,178.65|18,268,280.97|14,228,668.58
包含商誉的资产组的可收回金额8|464,150,000.00|151,170,000.00|24,260,000.00|36,160,000.00
减值损失9=if( 8-7>0,0, 8-7)||||
其中:应确认的商誉减值损失10=if(9>5,5,9)||||
被审计单位享有的股权份额(11)|51.00%|100.00%|100.00%|100.00%
被审计单位应确认的商誉减值损失(12)=(11)*10||||
项目|河南佐今明大药房健康管理股份有限公司|湛江天马大药房连锁有限公司|保定市益民医药零售连锁有限公司|信阳大参林百姓福医药连锁有限公司
商誉账面余额1|104,792,346.92|161,940,839.74|32,561,825.16|24,309,595.10
商誉减值准备余额2||||
商誉账面价值3=2-1|104,792,346.92|161,940,839.74|32,561,825.16|24,309,595.10
未确认归属于少数股东权益的商誉价值4|100,682,843.12||31,284,890.84|23,356,277.65
调整后的商誉账面价值5=3+4|205,475,190.04|161,940,839.74|63,846,716.00|47,665,872.75
资产组的账面价值6|9,430,995.59|10,780,364.60|2,546,762.68|7,343,392.24
包含整体商誉的资产组账面价值7=5+6|214,906,185.63|172,721,204.34|66,393,478.68|55,009,264.99
包含商誉的资产组的可收回金额8|243,170,000.00|246,130,000.00|100,800,000.00|164,930,000.00
减值损失9=if( 8-7>0,0, 8-7)||||
其中:应确认的商誉减值损失10=if(9>5,5,9)||||
被审计单位享有的股权份额(11)|51.00%|100.00%|51.00%|51.00%
被审计单位应确认的商誉减值损失(12)=(11)*10||||
项目|驻马店大参林百姓连锁药店有限公司|常州市健安堂大药房有限公司|成都一丰立康医药连锁有限责任公司|大参林泰华(绥化)医药连锁有限公司
商誉账面余额1|24,890,688.19|17,610,818.83|40,436,522.71|105,570,510.57
商誉减值准备余额2||||
商誉账面价值3=2-1|24,890,688.19|17,610,818.83|40,436,522.71|105,570,510.57
未确认归属于少数股东权益的商誉价值4|23,914,582.77|9,482,748.59|38,850,776.72|45,244,504.53
调整后的商誉账面价值5=3+4|48,805,270.96|27,093,567.42|79,287,299.43|150,815,015.10
资产组的账面价值6|6,446,844.88|1,191,541.66|2,427,595.56|9,129,825.58
包含整体商誉的资产组账面价值7=5+6|55,252,115.84|28,285,109.08|81,714,894.99|159,944,840.68
包含商誉的资产组的可收回金额8|144,110,000.00|30,970,000.00|83,310,000.00|178,800,000.00
减值损失9=if( 8-7>0,0, 8-7)||||
其中:应确认的商誉减值损失10=if(9>5,5,9)||||
被审计单位享有的股权份额(11)|51.00%|65.00%|51.00%|70.00%
被审计单位应确认的商誉减值损失(12)=(11)*10||||
项目|大参林福斯特(大庆)医药连锁有限公司|德阳大成家人健康连锁药房有限公司|河北益友医药连锁有限公司|河南大参林炎黄大药房连锁有限公司
商誉账面余额1|24,139,892.89|28,790,154.21|21,668,617.75|54,848,979.67
商誉减值准备余额2||||
商誉账面价值3=2-1|24,139,892.89|28,790,154.21|21,668,617.75|54,848,979.67
未确认归属于少数股东权益的商誉价值4|18,967,058.70|27,661,128.55|17,025,342.52|52,698,039.29
调整后的商誉账面价值5=3+4|43,106,951.59|56,451,282.76|38,693,960.27|107,547,018.96
资产组的账面价值6|198,545.14|8,936,775.10|1,355,229.11|4,270,825.71
包含整体商誉的资产组账面价值7=5+6|43,305,496.73|65,388,057.86|40,049,189.38|111,817,844.67
包含商誉的资产组的可收回金额8|49,630,000.00|108,930,000.00|57,640,000.00|186,430,000.00
减值损失9=if( 8-7>0,0, 8-7)||||
其中:应确认的商誉减值损失10=if(9>5,5,9)||||
被审计单位享有的股权份额(11)|56.00%|51.00%|56.00%|51.00%
被审计单位应确认的商誉减值损失(12)=(11)*10||||
项目|大参林灵峰(哈尔滨)医药连锁有限公司|大参林(湖北)药业连锁有限公司|淮滨县大参林康民堂医药连锁有限公司|牡丹江大参林天利医药连锁有限公司
商誉账面余额1|43,362,369.44|24,586,849.07|9,348,790.62|48,085,377.70
商誉减值准备余额2||||
商誉账面价值3=2-1|43,362,369.44|24,586,849.07|9,348,790.62|48,085,377.70
未确认归属于少数股东权益的商誉价值4|41,661,884.36|23,622,658.91|8,982,171.38|30,743,110.33
调整后的商誉账面价值5=3+4|85,024,253.80|48,209,507.98|18,330,962.00|78,828,488.03
资产组的账面价值6|4,746,500.14|4,680,078.66|2,951,148.12|9,001,761.13
包含整体商誉的资产组账面价值7=5+6|89,770,753.94|52,889,586.64|21,282,110.12|87,830,249.16
包含商誉的资产组的可收回金额8|125,620,000.00|56,180,000.00|74,720,000.00|106,430,000.00
减值损失9=if( 8-7>0,0, 8-7)||||
其中:应确认的商誉减值损失10=if(9>5,5,9)||||
被审计单位享有的股权份额(11)|51.00%|51.00%|51.00%|61.00%
被审计单位应确认的商誉减值损失(12)=(11)*10||||
项目|南通遂生堂大药房有限公司|齐齐哈尔大参林新特药品连锁有限公司|泰州市国泰大药房连锁有限公司|大参林(扬州)医药连锁有限公司
商誉账面余额1|11,401,224.72|21,345,757.91|36,501,380.13|5,355,252.88
商誉减值准备余额2||||
商誉账面价值3=2-1|11,401,224.72|21,345,757.91|36,501,380.13|5,355,252.88
未确认归属于少数股东权益的商誉价值4|1,266,802.75|16,771,666.93|19,654,589.30|5,145,242.96
调整后的商誉账面价值5=3+4|12,668,027.47|38,117,424.84|56,155,969.43|10,500,495.84
资产组的账面价值6|857,016.80|2,902,615.43|2,973,020.52|3,558,210.91
包含整体商誉的资产组账面价值7=5+6|13,525,044.27|41,020,040.27|59,128,989.95|14,058,706.75
包含商誉的资产组的可收回金额8|23,050,000.00|45,000,000.00|73,480,000.00|20,170,000.00
减值损失9=if( 8-7>0,0, 8-7)||||
其中:应确认的商誉减值损失10=if(9>5,5,9)||||
被审计单位享有的股权份额(11)|90.00%|56.00%|65.00%|51.00%
被审计单位应确认的商誉减值损失(12)=(11)*10||||
项目|微山县润康广场医药连锁有限公司|重庆市万家燕大药房连锁有限公司|梅州市益民大药房连锁有限公司20家门店资产、商品及业务|广东万寿堂医药连锁有限公司35家门店资产、商品及业务
商誉账面余额1|33,071,545.82|88,789,810.25|15,000,000.00|32,530,000.00
商誉减值准备余额2||||
商誉账面价值3=2-1|33,071,545.82|88,789,810.25|15,000,000.00|32,530,000.00
未确认归属于少数股东权益的商誉价值4|31,774,622.45|85,307,856.91||
调整后的商誉账面价值5=3+4|64,846,168.27|174,097,667.16|15,000,000.00|32,530,000.00
资产组的账面价值6|2,520,219.96|10,735,101.83|3,705,218.37|2,971,476.28
包含整体商誉的资产组账面价值7=5+6|67,366,388.23|184,832,768.99|18,705,218.37|35,501,476.28
包含商誉的资产组的可收回金额8|91,180,000.00|318,000,000.00|21,010,000.00|52,470,000.00
减值损失9=if( 8-7>0,0, 8-7)||||
其中:应确认的商誉减值损失10=if(9>5,5,9)||||
被审计单位享有的股权份额(11)|51.00%|51.00%|100.00%|100.00%
被审计单位应确认的商誉减值损失(12)=(11)*10||||
项目|洛阳大参林连锁药店有限公司|广东药交商务服务有限责任公司|陕西万百泉大药房医药连锁有限公司|大参林(湖北)药业有限公司
商誉账面余额1|27,327,567.29|11,195,845.60|41,843,695.91|4,294,756.51
商誉减值准备余额2||||
商誉账面价值3=2-1|27,327,567.29|11,195,845.60|41,843,695.91|4,294,756.51
未确认归属于少数股东权益的商誉价值4|26,255,897.99|10,756,792.83|32,877,189.64|
调整后的商誉账面价值5=3+4|53,583,465.28|21,952,638.43|74,720,885.55|4,294,756.51
资产组的账面价值6|3,027,518.10|10,697.00|1,712,137.32|215,103.86